SCHEDULE: Vanguard Reports 13.82% Stake in Organon & Co

The Vanguard Group has disclosed a 13.82% beneficial ownership stake in Organon & Co, holding over 35.9 million shares as of September 30, 2025.

Summary

• The Vanguard Group beneficially owns 35,927,524 shares of Organon & Co common stock.
• This represents 13.82% of Organon & Co's outstanding common stock.
• Vanguard holds sole dispositive power over 33,922,797 shares and shared dispositive power over 2,004,727 shares.
• Vanguard holds shared voting power over 1,689,621 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Organon & Co.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership by an institutional investor, providing neutral information without explicit positive or negative commentary on the issuer's performance or outlook.

Positives

• The disclosure of a significant 13.82% stake by The Vanguard Group, a major institutional investor, signals strong institutional confidence in Organon & Co's long-term prospects and stability.

Future Outlook

NA

Industry Context

This filing reflects a standard disclosure by a large asset manager regarding its passive investment holdings in a publicly traded pharmaceutical company. It does not provide specific insights into Organon & Co's operational performance or industry position, but rather details the ownership structure by a significant institutional investor.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holding, potentially reinforcing confidence in the company's shareholder base.
• Management: Awareness of a large, passive institutional investor's stake, which typically implies a focus on long-term value creation rather than activist intervention.

Key Dates

Keywords

Organon & Co, Vanguard Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake